The dual role of the urokinase receptor system in pericellular proteolysis and cell adhesion: Implications for cardiovascular function

Basic Research in Cardiology

Volumn 94, Issue 5, 1999, Pages 315-321

  Preissner, K T ^a   Kanse, S M ^a   Chavakis, T ^a   May, A E ^b  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cell adhesion; Integrins; Proteolysis; Urokinase receptor; Vascular pathologies

Indexed keywords

INTEGRIN; PROTEINASE; UROKINASE RECEPTOR;

ATHEROSCLEROSIS; CARDIOVASCULAR FUNCTION; CELL ADHESION; CELL INTERACTION; CELL INVASION; CELL MIGRATION; HUMAN; HUMAN CELL; PROTEIN DEGRADATION; RESTENOSIS; REVIEW; THROMBOSIS; TUMOR GROWTH;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CARDIOVASCULAR SYSTEM; CELL ADHESION; EXTRACELLULAR MATRIX; HUMANS; MODELS, CARDIOVASCULAR; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032856790     PISSN: 03008428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s003950050157     Document Type: Review

References (65)

1. Altieri DC, Morrissey JH, Edgington TS (1988) Adhesive receptor Mac-1 coordinates the activation of factor X on stimulated cells of monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 85: 7462-7466
2. Andreasen PA, Kjoller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis. Int J Cancer 72: 1-22
3. Behrendt N, Stephens RW (1998) The urokinase receptor. Fibrinol Proteol 12: 191-204
4. Blasi F (1997) uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 18: 415-417
5. Bohuslav J, Horesjsi V, Hansmann C, Stöckl J, Weidle UH, Majdic O, Bartke I, Knapp W, Stockinger H (1995) Urokinase plasminogen activator receptor, β2-integrins, and scr-kinases within a single receptor complex of human monocytes. J Exp Med 181: 1381-1390
6. Brooks PC, Clark RAF, Cheresh DA (1994) Requirement of vascular integrin ανβ3 for angiogenesis. Science 264: 569-571
7. Brooks PC, Montgomery AM, Rosenfeld M, Reisfeld RA, Hu T, Klier G, Cheresh DA (1994) Integrin avβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 79: 1157-1164
8. Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Anti-integrin avβ3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96: 1815-1822
9. Brunner G, Preissner KT (1994) Pericellular enzymatic hydrolysis: implications for the regulation of cell proliferation in the vessel wall and the bone marrow. Blood Coagul Fibrinol 5: 625-639
10. Bu G, Warshawsky I, Schwartz AL (1994) Cellular receptors for the plasminogen activators. Blood 83: 3427-3436
11. Butcher EC, Picker LJ (1996) Lymphocyte homing and homeostasis. Science 272: 60-66
12. Carmeliet P, Collen D (1995) Role of the plasminogen/plasmin system in thrombosis, hemostasis, restenosis and atherosclerosis. Trends Cardiovasc Med 5: 117-122
13. Carmeliet P, Collen D (1997) Molecular genetics of the fibrinolytic and coagulation systems in haemostasis, thrombogenesis, restenosis and atherosclerosis. Curr Opin Lipidol 8: 118-125
14. Carmeliet P, Collen D (1998) Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thromb Res 91: 255-286
15. Carmeliet P, Schoonhans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan R (1994) Physiological consequences of loss of plasminogen activator gene function in mice. Nature 368: 419-424
16. Carriero MV, Del Vecchio S, Franco P, Potena MI, Chiaradonna F, Botti G, Stoppelli MP, Salvatore M (1997) Vitronectin binding to urokinase receptor in human breast cancer. Clin Cancer Res 3: 1299-1308
17. Chapman HA (1997) Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr Opin Cell Biol 9: 714-724
18. Chavakis T, Kanse SM, Yutzy B, Lijnen HR, Preissner KT (1998) Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 91: 1-9
19. Ciambrone GJ, McKeown-Longo PJ (1992) Vitronectin regulates the synthesis and localization of urokinase-type plasminogen activator in HT-1080 cells. J Biol Chem 267: 13617-13622
20. Dahlbäck K, Löfberg H, Aluments J, Dahlbäck B (1989) Immunohistochemical demonstration of age-related deposition of vitronectin (S-protein of complement) and terminal complement complex on dermal elastic fibers. J Invest Dermatol 92: 727-733
21. de Boer HC, Preissner KT, Bouma BN, de Groot PG (1995) Internalization of vitronectin-thrombin-antithrombin complex by endothelial cells leads to deposition of the complex into the subendothelial matrix. J Biol Chem 270: 30733-30740
22. Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134: 1563-1571
23. Duffy MJ (1993) Urokinase-type plasminogen activator and malignancy. Fibrinolysis 7: 295-302
24. Dumler I, Hucho F, Gulba D (1997) Signal transduction via urokinase receptor-is a transmembrane adapter molecule really necessary. Fibrinol Proteol 11: 165-169
25. Estreicher A, Mühlhauser J, Carpentier J-L, Orci L, Vassalli J-D (1990) The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J Cell Biol 111: 783-792
26. Galis Z, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P (1995) Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 748: 501-507
27. Hammes HP, Brownlee M, Joncyk A, Sutter A, Preissner KT (1996) Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nature Med 2: 529-533
28. Hynes RO (1992) Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 69: 11-25
29. Itano M, Tsuchiya S, Minegishi N, Fujie H, Minegishi M, Monta S, Yambe T, Ohashi Y, Masuda T, Koike T et al. (1995) Establishment and characterization of a novel human immature megakaryoblastic leukemia cell line, M-MOK, dependen on flbbroblasts for its viability. Exp Hematol 23: 1301-1309
30. Jänicke F, Schmitt M, Hafter R, Hollrieder A, Babic R, Ulm K, Gössner W, Graeff H (1990) Urokinase-type plasminogen activator (u-PA) antigen is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
31. Kanse SM, Kost C, Wilhelm OG, Andreasen PA, Preissner KT (1996) The urokinase receptor is a major vitronectin binding protein on endothelial cells. Exp Cell Res 224: 344-353
32. Kjoller L, Kanse SM, Kirkegaard T, Rodenburg KW, Ronne E, Goodman SL, Preissner KT, Ossowski L, Andreasen PA (1997) Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp Cell Res 232: 420-429
33. Kolanus W, Nagel W, Schiller B, Zeitlmann L, Godar S, Stockinger H, Seed B (1996) αLβ2-integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1, a cytoplasmic regulatory molecule. Cell 86: 233-242
34. Kook YH, Adamski J, Zelent A, Ossowski L (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983-3991
35. Lijnen HR, Vanhoef B, Lupu F, Moons L, Carmeliet P, Collen D (1998) Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 18: 1035-1045
36. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EKO (1995) Plasminogen activator expression in human atherosclerotic lesions. Arterioscl Thromb Vasc Biol 15: 1444-1455
37. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT (1998) Urokinase receptor (CD87) regulates leukocyte recruitment via β2-integrins in vivo. J Exp Med 188: 1029-1037
38. Metz CN, Brunner G, Choi-Muira NH, Nguyen H, Gabrilove J, Caras IW, Altsuzuler N, Rifkin DB, Wilson EL, Davitz MA (1994) Release of GPI-anchored membrane proteins by a cell-associated GPI-specific phospholipase D. EMBO J 13: 1741-1751
39. Min HY, Doyle LV, Vitt CR, Zandonella CL, Stratton-Thomas JR, Shuman MA, Rosenberg S (1996) Urokinase receptor antangonist inhibit angiogenesis and primary tumor growth in syngeneic mice. Cancer Res 56: 2428-2433
40. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M (1999) Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 99: 420-426
41. Murphy G, Docherty AJP (1992) The matrix metalloproteinase and their inhibitors. Am J Respir Cell Mol Biol 7: 120-125
42. Ossowski L, Clunie G, Masucci M, Blasi F (1993) In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion. J Cell Biol 115: 1107-1112
43. Panetti TS, McKeown-Longo PJ (1993) The ανβ5 integrin receptor regulates receptor-mediated endocytosis of vitronectin. J Biol Chem 268: 11492-11495
44. Petty HR, Todd RF (1996) Integrins as promiscuous signal transduction devices. Immunol Today 17: 209-212
45. Ploug M, Ronne E, Behrendt N, Jensen AL, Blasi F, Dano K (1991) Cellular receptor for urokinase plasminogen activator Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266: 1926-1933
46. Pöllänen J, Hedeman K, Nielsen LS, Dano K, Vaheri A (1988) Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol 106: 87-95
47. Preissner KT, May AE, Wohn KD, Germer M, Kanse SM (1997) Molecular crosstalk between adhesion receptors and proteolytic cascades in vascular remodeling. Thromb Haemostas 78: 88-95
48. Preissner KT, Pötzsch B (1995) Vessel wall-dependent metabolic pathways of the adhesive proteins, von-Willebrand-factor and vitronectin. Histol Histopathol 10: 239-251
49. Reilly D, Christensen K, Duch M, Nolan N, Duffy MJ, Andreasen PA (1992) Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Canc 50: 208-214
50. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-1582
51. Schmits R, Kundig TM, Baker DM, Shumaker G, Simard JJL, Duncan G, Wakeharn A, Shahinjan A, van der Heiden A, Bachmann MF (1996) LFA-1-deficient mice show normal CTL responses to virus, but fail to reject immunogenic tumor. J Exp Med 183: 1415-1426
52. Schmitt M, Wilhelm O, Jänicke F, Magdolen V, Reuning U, Ohi H, Moniwa N, Kobayashi H, Weidle U, Graeff H (1995) Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis. J Obstet Gynaecol 21: 151-165
53. Schonbeck U, Mach F, Sukhova GK, Atkinson E, Levesque E, Herman M, Graber P, Basset P, Libby P (1999) Expression of stromelysin-3 in atherosclerotic lesions: regulation via CD40-CD40 ligand signaling in vitro and in vivo. J Exp Med 189: 843-853
54. Senger DR (1996) Molecular framework for angiogenesis A complex web of interactions between extravasated plasma proteins and endothelial cell proteins induced by angiogenic cytokines. Am J Path 149: 1-7
55. Simon DI, Rao NK, Xu H, Wei Y, Majdic O, Ronne O, Kobzik L, Chapman HA (1996) Mac-1 (CD11b/CD18) and the urokinase receptor (CD87) form a functional unit on monocytic cells. Blood 88: 3185-3194
56. Sitrin RG, Todd RF, Petty HR, Brock TG, Shollenberger SB, Albrecht E, Gyetko MR (1996) The urokinase receptor (CD87) facilitates CD11B/CD18-mediated adhesion of human monocytes. J Clin Invest 97: 1942-1951
57. Sligh JE, Ballantyne CM, Rich SS, Hawkins HK, Smith CW, Bradley A, Beaudet AL (1993) Inflammatory and immune rersponses are impaired in mice deficient in intercellular adhesion molecule 1. Proc Natl Acad Sci USA 90: 8529-8533
58. Stefansson S, Lawrence DA (1996) The serpin PAI-1 inhibits cell megration by blocking integrin ανβ3 binding to vitronectin. Nature 383: 441-443
59. Waltz DA, Chapman HA (1994) Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746-14750
60. Wei Y, Lukashev M, Simon DI, Bodary SC, Rosenberg S, Doyle MV, Chapman HA (1996) Regulation of integrin function by the urokinase receptor. Science 273: 1551-1555
61. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388
62. Wohn KD, Schmidt T, Kanse SM, Yutzi B, Germer M, Morgenstern E, Preissner KT (1999) The role of plasminogen activator inhibitor-1 as inhibitor of platelet and megakaryoblastic cell adhesion. Br J Haematol 104: 901-908
63. Xue W, Kindzelskii AL, Todd RF, Petty HR (1994) Physical association of complement receptor type 3 and urokinase-type plasminogen activator receptor in neutrophil membranes. J Immunol 152: 4630
64. Xue W, Mizukami I, Todd RF, Petty HR (1997) Urokinase-type plasminogen activator receptors associate with β1- and β3-integrins of fibrosarcoma cells - dependence on extracellular matrix components. Canc Res 57: 1682-1689
65. Yebra M, Parry GCN, Stromblad S, Mackman N, Rosenberg S, Mueller BM, Cheresh DA (1996) Requirement of receptor-bound urokinase-type plasminogen activator for integrin ανβ3-directed cell migration. J Biol Chem 271: 29393-29399